Ballard Spahr advised Pyramid Biosciences on the deal. Clinical-stage biotechnology company Pyramid Biosciences, Inc. announced the development of a global licensing deal for two cancer therapies worth...
Ballard Spahr advised Pyramid Biosciences on the deal. Clinical-stage biotechnology company Pyramid Biosciences, Inc. announced the development of a global licensing deal for two cancer therapies worth...
You must be a Standard 1 Year member to access this content.